Video navigation menu

• HF and diabetes: a prevalent combination with poor prognosis 0:13
• What the new ESC HF guidelines say about current anti-diabetic therapies in HF - insulin 2:18
• Sulfonylureas should be used with caution 4:10
• Metformin is safe and the treatment of choice in HF patients with diabetes 5:09
• TZDs are not recommended in patients with HF 5:58
• GLP-1 analogues and DPP4 inhibitors potentially increase risk, but safety data in HF is lacking 7:17
• Overview of the ESC HF 2016 guideline recommendations on treatment of HF and diabetes 9:35